Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CX3CR1, also known as the fractalkine receptor or G-protein coupled receptor 13 (GPR13), is a transmembrane protein belonging to the G protein-coupled receptor (GPCR) family. It is the only known member of the CX3C chemokine receptor subfamily and specifically binds to its unique ligand, CX3CL1 (fractalkine). It mediates chemotaxis, adhesion, and cell survival. Dysregulation is implicated in multiple diseases, including atherosclerosis, neurodegenerative disorders and cancer. Polymorphisms in CX3CR1 can alter binding affinity for fractalkine and have been associated with disease susceptibility.
Triggers intracellular signaling cascades through G proteins; Modulates gene expression related to survival, proliferation, adhesion molecules; Acts via cell-cell contact or by creating gradients for directed migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CX3C motif chemokine receptor 1 (CX3CR1).